



Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.



# Multisystem inflammatory syndrome in children with COVID-19

Michael Gottlieb, MD<sup>a,\*</sup>, Rachel Bridwell, MD<sup>b</sup>, Joseph Ravera, MD<sup>c</sup>, Brit Long, MD<sup>b</sup>

<sup>a</sup> Department of Emergency Medicine, Rush University Medical Center, USA

<sup>b</sup> Department of Emergency Medicine, Brooke Army Medical Center, USA

<sup>c</sup> Department of Surgery, Division of Emergency Medicine, University of Vermont, USA

## ARTICLE INFO

### Article history:

Received 14 March 2021

Received in revised form 19 May 2021

Accepted 28 May 2021

### Keywords:

COVID-19

MIS-C

Pediatrics

## ABSTRACT

**Background:** Multisystem inflammatory syndrome in children (MIS-C) is a dangerous pediatric complication of COVID-19.

**Objective:** The purpose of this review article is to provide a summary of the diagnosis and management of MIS-C with a focus on management in the acute care setting.

**Discussion:** MIS-C is an inflammatory syndrome which can affect nearly any organ system. The most common symptoms are fever and gastrointestinal symptoms, though neurologic and dermatologic findings are also well-described. The diagnosis includes a combination of clinical and laboratory testing. Patients with MIS-C will often have elevated inflammatory markers and may have an abnormal electrocardiogram or echocardiogram. Initial treatment involves resuscitation with careful assessment for cardiac versus vasodilatory shock using point-of-care ultrasound. Treatment should include intravenous immunoglobulin, anticoagulation, and consideration of corticosteroids. Interleukin-1 and/or interleukin-6 blockade may be considered for refractory cases. Aspirin is recommended if there is thrombocytosis or Kawasaki disease-like features on echocardiogram. Patients will generally require admission to an intensive care unit.

**Conclusion:** MIS-C is a condition associated with morbidity and mortality that is increasingly recognized as a potential complication in pediatric patients with COVID-19. It is important for emergency clinicians to know how to diagnose and treat this disorder.

© 2021 Elsevier Inc. All rights reserved.

## 1. Introduction

Multisystem inflammatory syndrome in children (MIS-C) is a condition among pediatric patients with coronavirus disease of 2019 (COVID-19), resulting in inflammation of a variety of organ systems, including the heart, lungs, brain, kidneys, gastrointestinal system, skin, and eyes. There are a distinct set of clinical criteria, which are displayed in [Table 1](#). The true global incidence of MIS-C is uncertain, but it appears to be rare. The first reported cases occurred in the United Kingdom, followed by reports from Canada, Europe, South Africa, and the United States [1–10]. Reports estimate the incidence in those under age 21 years to be 2 per 100,000 persons with an overall incidence among children with COVID-19 of 322 per 100,000 persons [1–4]. As of May 2021, 3742 cases of MIS-C have been reported in the United States, with 35 deaths related to MIS-C [1,3]. Most studies demonstrate a lag of 2–6 weeks between COVID-19 infection and developing MIS-C [1,2,5]. Over 70% of MIS-C cases occur in previously healthy patients, with obesity and asthma being the most common underlying medical conditions [1,7,11].

While MIS-C and Kawasaki disease (KD) share some overlap in symptoms, the epidemiology of MIS-C differs from that of KD. The median age of confirmed cases in MIS-C is 7–11 years, whereas 80–90% of cases of KD occur in children under age 5 years of age [5,12,13]. Males are more commonly affected in both MIS-C (up to 59%) and KD (up to 60%) [4,5,7,11,14,15]. The rates of MIS-C vary by race, with studies reporting 25–62% of patients being Black, 30–40% being Hispanic, 15–25% being White, and up to 28% being Asian [4,5,7,11,14]. By comparison, KD more commonly affects infants and young children of Asian descent, with an incidence of 30 per 100,000 for those of Asian or Pacific Islander descent compared with the lowest incidence among Caucasians (12 per 100,000) [15–18].

The complications of MIS-C can be severe, including cardiogenic shock or distributive shock with poor vasomotor tone. In one systematic review of 917 patients, 11 (1.9%) patients died [19]. Most patients with cardiac involvement (including depressed ventricular function or arrhythmias) typically recover. However, 20–45% of patients may still have a mildly depressed ejection fraction at the time of hospital discharge [19–22]. Given

\* Corresponding author.

E-mail address: [michaelgottliebmd@gmail.com](mailto:michaelgottliebmd@gmail.com) (M. Gottlieb).

**Table 1**  
MIS-C diagnostic criteria.

| Criteria     | CDC [3]  | WHO [66]   | RCPCH [67]   |
|--------------|--|--|--|
| Age          | <21 years  | <19 years  | All children (age not defined)                             |
| Fever        | ≥38C for ≥24 h or subjective fever lasting ≥ 24 h  | Fever ≥ 3 days   | Persistent fever ≥ 38.5C                                   |
| Clinical     | Evidence of clinically severe illness requiring hospitalization, with multisystem organ involvement (≥2 of the following: cardiac, renal, respiratory, hematologic, GI, dermatologic, or neurologic) | At least 2 of the following:<br>1) Rash, conjunctivitis, mucocutaneous inflammation<br>2) Hypotension or shock<br>3) Cardiac involvement*<br>4) Coagulopathy<br>5) Acute GI symptoms | Single or multiorgan dysfunction and additional features** |
| Inflammation | At least one of the following: elevated CRP, ESR, fibrinogen, procalcitonin, D-dimer, ferritin, lactic acid dehydrogenase, IL-6, elevated neutrophils, reduced lymphocytes, low albumin              | Elevated CRP, ESR, procalcitonin   | Neutrophilia, elevated CRP, and lymphopenia                |
| SARS-CoV-2   | Positive for current or recent SARS-CoV-2 infection by RT-PCR, serology, or antigen test, or COVID-19 exposure within the 4 weeks prior to symptom onset   | Positive for current or recent SARS-CoV-2 infection by RT-PCR, serology, or antigen test, or likely COVID-19 exposure  | Positive or negative RT-PCR                                |
| Exclusion    | No alternative diagnosis   | No obvious microbial cause   | Exclusion of other infections                              |

CDC, Centers for Disease Control and Prevention; WHO, World Health Organization; RCPCH, Royal College of Paediatric and Child Health; GI, gastrointestinal; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; IL-6, interleukin-6; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; RT-PCR, reverse transcription polymerase chain reaction; NT-proBNP, N-terminal pro-brain natriuretic peptide.

\* Cardiac involvement defined by the WHO MIS-C case definition: features of myocardial dysfunction, pericarditis, valvulitis, or coronary abnormalities (including echocardiogram findings or elevated troponin/NT-proBNP).

\*\* Additional features for the RCPCH definition: abdominal pain, confusion, conjunctivitis, cough, diarrhea, headache, lymphadenopathy, mucous membrane changes, neck swelling, rash, respiratory symptoms, sore throat, swollen hands and feet, syncope, vomiting.

the significant impact of MIS-C on affected patients, it is important for the emergency clinician to be aware of this condition.

## 2. Methods

Authors searched PubMed and Google Scholar for articles using a combination of the keywords “MIS-C”, “Multisystem Inflammatory Syndrome”, “COVID-19”, and “pediatric” from inception to May 18, 2021. The literature search was restricted to studies published in English. Authors reviewed all relevant articles and decided which studies to include for the review by consensus. When available, systematic reviews and meta-analyses were preferentially selected. These were followed sequentially by randomized controlled trials, prospective studies, retrospective studies, case reports, and other narrative reviews when alternate data were not available. A total of 67 articles were selected for inclusion in this narrative review.

## 3. Discussion

### 3.1. Pathophysiology and microbiology

The pathophysiology remains incompletely understood. The syndrome has been hypothesized to result from an abnormal immune response to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), but with a distinct immunophenotype when compared to KD [23–25]. Endothelial dysfunction associated with SARS-CoV-2 and cytokine storm have been proposed as the mechanisms of end organ injury in MIS-C [25]. One study suggests the SARS-CoV-2 spike protein may directly activate the immune system, functioning as a superantigen similar to Staphylococcal enterotoxin B [25,26]. This abnormal immune response may result in multiorgan injury and failure. Myocardial injury may be associated with systemic inflammation, viral myocarditis, cardiomyopathy, hypoxia, and/or coronary vessel involvement resulting in ischemia [25,27]. Autopsy findings have demonstrated evidence of pericarditis, myocarditis, and endocarditis with infiltration of inflammatory cells, as well as the presence of SARS-CoV-2 virus in cardiac tissue [28].

### 3.2. History and physical examination

The presentation of MIS-C varies and can mimic a variety of other conditions, particularly KD. Table 2 depicts differences between MIS-C and KD. Patients with MIS-C may present with gastrointestinal symptoms (abdominal pain, vomiting, or diarrhea are present in 60–100%), neurocognitive symptoms (headache, decreased mental status, or lethargy are present in 29–58%), respiratory symptoms (21–65%), sore throat (10–16%), and myalgias (8–17%) [1,4,7,10,11,14,19,20,29–31]. Severe cases may present with myocardial dysfunction (55%), cardiogenic shock (66%), multisystemic organ failure, and cytokine storm, which can overlap with presentations of KD, septic shock, secondary hemophagocytic lymphohistiocytosis, and toxic shock syndrome [10,19,32–34].

In one multinational survey of 183 pediatric patients with MIS-C, fever was present in 100% of cases [35]. Shock was present in 43.2% and was more common in older children (mean 9 years vs 7 years) [35]. A meta-analysis demonstrated similar results with 100% of patients presenting with fever, followed by 73.3% patients presenting with diarrhea or abdominal pain, and 68.3% patients presenting with

**Table 2**  
Distinctions between MIS-C and Kawasaki disease [35]

| MIS-C   | Kawasaki disease  |
|---|---|
| - More commonly affects older children and adolescents (>7 years)   | - More commonly affects younger children and infants (<5 years)   |
| - GI symptoms very common   | - GI symptoms not common  |
| - Myocardial dysfunction and shock more common  | - Myocardial dysfunction and shock less common                    |
| - Inflammatory markers [CRP (12–22 times normal values), ferritin (1–3 times normal values), D-dimer (10–20 times normal values)] more significantly elevated | - Inflammatory markers (CRP, ferritin, D-dimer) not very elevated |
| - Absolute lymphocyte count and platelet counts are low   | - Leukocytosis and thrombocytosis are common                      |

MIS-C, Multisystem Inflammatory Syndrome in Children; GI, gastrointestinal; CRP, C reactive protein.

vomiting [30]. The vast majority of these patients will have fever for a minimum of 3 days, with a median duration of 4–6 days [30].

The physical examination of MIS-C patients can overlap with KD [32]. Conjunctivitis is present in 30–81% of patients with MIS-C, while rash is present in 45–76% [14,30,31,36]. The rash can have a variable appearance, including erythema, morbilliform, purpura, targetoid, or urticarial [37]. The majority of patients with MIS-C will exhibit abdominal tenderness on examination [30]. Multiorgan involvement is common in these patients, and cardiogenic or vasoplegic shock can occur in 32–76% of patients [1,7,11,27,28,32]. Patients may also present with mucous membrane involvement (27–76%), lymphadenopathy (6–16%), and swollen hands or feet (9–16%) [1,4,7,10,11,20,29–32,38–40]. Pleural effusions, pericardial effusions, and ascites can also occur in these patients [41]. Severe neurologic manifestations including seizures, altered mental status, encephalopathy, and meningoenzephalitis may occur in 6–15% of patients [1,7,11,27,28,31].

One study compared MIS-C patients with control patients presenting with febrile illnesses from other common outpatient conditions [42]. Between these groups, MIS-C patients reported higher temperatures (40 °C vs 38.9 °C), increased frequency of abdominal pain (odds ratio [OR]: 12.5), neck pain (OR: 536.5), conjunctivitis (OR: 31.3), oral mucosal irritation (OR: 11.8), extremity swelling or rash (OR: 99.9), and generalized rash (OR: 7.4) [42].

### 3.3. Diagnostic testing

The diagnostic evaluation of suspected MIS-C in a toxic-appearing patient (e.g., shock, dehydration, respiratory distress, neurologic changes) should include a complete blood cell count (CBC), electrolytes, renal and liver function, inflammatory markers (erythrocyte sedimentation rate [ESR] and C-reactive protein [CRP]), albumin, coagulation panel, D-dimer, SARS-CoV-2 testing (polymerase chain reaction [PCR] and/or serologies if available), troponin, and brain natriuretic peptide (BNP). Due to the overlapping presentation with sepsis, blood cultures should also be obtained. If available, ferritin, fibrinogen, and procalcitonin can assist the inpatient team.

For patients who are otherwise well-appearing, the American College of Rheumatology recommends a tiered system of testing [43]. In this testing strategy, those who appear well but in whom MIS-C is a consideration should be tested with CBC, electrolytes, renal and liver function, CRP, and ESR [43]. If CRP  $\geq$  5 mg/dL or ESR  $\geq$  40 mm/h are found on testing combined with one of the following other laboratory abnormalities (absolute lymphocyte count  $<$  1.5, platelet count  $<$  150,000, sodium  $<$  135 mmol/L, neutrophilia, or hypoalbuminemia), then full testing as described above is recommended [43]. In order to avoid repeat blood draws in this population, it is recommended to obtain extra blood tubes for this additional testing if they are otherwise well-appearing, but MIS-C is suspected.

Elevated inflammatory markers are common, with 92% of patients having at least 4 of the following abnormalities: elevated ESR (75–80%), elevated D-dimer (67–100%), elevated CRP (90–100%), lymphocytopenia (80–95%), neutrophilia (68–90%), elevated ferritin (55–76%), hypoalbuminemia (48–95%), anemia (70%), thrombocytopenia (31–80%), or increased liver enzymes (62–70%) [10,19,35,44–47]. One large study found that inflammatory markers were higher and platelets were lower among those presenting in shock [35]. Cardiovascular involvement is commonly seen, with elevations in BNP/pro-BNP (73–95%) and troponin (50–93%) [10,19,31,35,44–46]. Acute kidney injury can occur in 8–52%, and laboratory evaluation may also reveal elevated lactate dehydrogenase (10–60%) or hypertriglyceridemia (70%) if these laboratory tests are obtained [1,7,11,27,28].

Because of the relatively broad presentations of MIS-C, pediatric emergency departments have sought to screen for these patients using a variety of physical examination and laboratory markers. One tertiary pediatric emergency department found that fever for more than 24 h plus 2 system involvement (gastrointestinal, mucocutaneous,

lymphadenopathy) and at least 2 of 4 laboratory criteria above these set thresholds (CRP  $\geq$  87.5 mg/L, troponin  $I \geq$  17 ng/L, ferritin  $\geq$  121.6 ng/mL, D-dimer  $\geq$  1.07 mg/L fibrinogen equivalent units) had a sensitivity of 92% and a specificity of 83% [48]. Elevated CRP values, higher neutrophil counts, lower lymphocyte counts, elevated troponin, and lower serum albumin are associated with a greater risk of shock [10].

All patients with concern for MIS-C should receive an electrocardiogram (ECG). Arrhythmias are present in 12–21% of patients [1,7,11,27,28,49]. The most common abnormal ECG findings are repolarization abnormalities, ischemic changes, and first-degree atrioventricular block [35]. Other findings include bundle branch blocks, prolonged QT intervals, and high-grade atrioventricular blocks [31]. In an image review of chest radiographs in MIS-C patients, cardiomegaly (63%), cardiogenic pulmonary edema (56%), and atelectasis (56%) were the most common findings [50]. Other findings on chest radiography in this population included pleural effusions (44–82%), pulmonary consolidations (6–73%), and radiographic findings of acute respiratory distress syndrome (13%) [50,51]. If obtained, abdominal imaging may demonstrate small volume ascites, bowel wall thickening, gallbladder wall thickening, or abdominal lymphadenopathy [52,53]. Echocardiograms are performed in the majority of patients with MIS-C due to both concern for coronary artery aneurysmal dilation as well as cardiac dysfunction due to myocarditis [30]. The most common finding is reduced left ventricular ejection fraction, seen in 45–60% of patients [10,11,22,27,54]. Coronary artery abnormalities can be present in 8–50% of patients [10,11,27,30,31]. Echocardiogram may also demonstrate pericardial effusions (28%), mitral regurgitation (43%), or tricuspid regurgitation (6%) [8,31,36,55]. Comprehensive echocardiography can also be used to assess coronary artery diameter, described using the Z-score. The Z-score is a measured of the coronary artery diameter compared to the average diameter for a child of the same size body surface area. Normal Z-score values are 0, with values greater than 0 representing coronary artery dilation [56,57].

### 3.4. Management

The first step in management should be resuscitation and hemodynamic stabilization in those with evidence of shock, which can be present in 32–76% of patients with MIS-C [1,7,11,27,28]. As these patients are often toxic appearing and present similar to those with septic shock, broad spectrum antibiotics are recommended, with blood cultures obtained prior to antibiotic therapy when feasible. Given the potential for cardiogenic versus vasodilatory shock, point-of-care ultrasound should be performed prior to aggressive volume resuscitation [58]. Patients who are volume depleted based on either clinical examination or ultrasound should receive fluid resuscitation [59]. Many children presenting in shock with MIS-C will present with vasodilatory shock, which may be refractory to adequate volume repletion. These patients may require vasopressor support with agents such as epinephrine or norepinephrine. However, epinephrine may be preferred if cardiac dysfunction is present. Further inotropic support can be provided with dobutamine or milrinone. Intubation and mechanical ventilation may be required; however, this is rarely due to a primarily pulmonary indication [6,10].

Once children have been appropriately resuscitated, consultation with pediatric specialists (e.g., cardiology, intensive care, rheumatology, infectious disease, and/or hematology) is recommended. The mainstay of treatment for MIS-C is immunomodulation in those with shock, cardiac involvement, or severe disease manifestations requiring intensive care unit admission [1,4,6–8,10,40,42,59,60]. While there are no prospective studies to date, expert recommendations using data extrapolated from KD advise intravenous immunoglobulin (IVIG) as first-line therapy in doses of 2 g/kg administered every 8–12 h [1,4,6–8,10,40,42,59–61]. Recent retrospective data have also suggested a potential benefit of early initiation of corticosteroids (prednisolone 2 mg/kg/day given intravenous or oral in 3 divided doses for



10 days), particularly in critically ill children and those on multiple vasoactive medications [1,4,7,20,43]. If patients do not respond to corticosteroids and IVIG, high-dose corticosteroids (10–30 mg/kg/day) should be considered [43]. Although not part of the initial management, further immunomodulation with IL-1 blockade (e.g., anakinra, canakinumab) and/or IL-6 blockade (e.g., tocilizumab) may be helpful in refractory cases [7,20,42]. In select cases, an intra-aortic balloon pump or extracorporeal membrane oxygenation may be considered [14,19,62–65].

Due to the proinflammatory state and potential for coronary artery and other thrombotic complications, anticoagulation is recommended. Patients should additionally receive full anticoagulation with either enoxaparin or warfarin if there is evidence of thrombosis, a severely depressed ejection fraction (ejection fraction < 35%), or a Z-score > 10 [7,20,43]. Low-dose aspirin (3–5 mg/kg/day; maximum 81 mg/day) is recommended if there is thrombocytosis (platelets  $\geq$  450,000) or KD-like features on echocardiography [7,20,43]. Aspirin should be avoided in patients with a platelet count of  $\leq$ 80,000 [43].

### 3.5. Disposition

Given the complexity of management, patients presenting to non-pediatric centers should be transferred to a pediatric tertiary care center once stabilized [11]. Due to the risk of significant complications and need for close monitoring, most patients (60–80%) with MIS-C will require admission to an intensive care setting [1,5,10,19,20].

## 4. Conclusion

MIS-C is a complication of COVID-19 which causes a multi-inflammatory syndrome that can affect nearly any organ system. Common signs and symptoms include fever, gastrointestinal symptoms, neurologic symptoms, and dermatologic findings. Most patients will have elevated inflammatory markers and may have an abnormal ECG or echocardiogram. Initial treatment involves resuscitation with careful assessment for cardiac versus vasodilatory shock using point-of-care ultrasound. Treatment includes IVIG, anticoagulation, and consideration of corticosteroids. IL-1 and/or IL-6 blockade may also be considered for refractory cases. Aspirin is recommended if there is thrombocytosis or KD-like features on echocardiogram. Patients will generally require admission to an intensive care unit.

### Meetings

None.

### Grants

None.

### Author contributions

None except listed.

### Declaration of competing interest

We have neither conflicts of interest nor financial support to disclose.

### Acknowledgements

This review does not reflect the views or opinions of the U.S. government, Department of Defense, U.S. Army, U.S. Air Force, Brooke Army Medical Center, or SAUSHEC EM Residency Program.

## References

- [1] Godfred-Cato S, Bryant B, Leung J, et al. COVID-19-associated multisystem inflammatory syndrome in children – United States, march–July 2020. *MMWR Morb Mortal Wkly Rep.* 2020;69:1074–80.
- [2] Morris SB, Schwartz NG, Patel P, et al. Case series of multisystem inflammatory syndrome in adults associated with SARS-CoV-2 infection – United Kingdom and United States, march–August 2020. *MMWR Morb Mortal Wkly Rep.* 2020;69:1450–6.
- [3] Health Department-Reported Cases of Multisystem Inflammatory Syndrome in Children (MIS-C) in the United States. Centers for Disease Control and Prevention. Updated May 3. Available at <https://www.cdc.gov/mis-c/cases/index.html>; 2021. Accessed May 18, 2021.
- [4] Dufort EM, Koumans EH, Chow EJ, et al. New York State and Centers for Disease Control and Prevention Multisystem Inflammatory Syndrome in Children Investigation Team. Multisystem Inflammatory Syndrome in Children in New York State. *N Engl J Med.* 2020 Jul 23;383(4):347–58.
- [5] Abrams JY, Godfred-Cato SE, Oster ME, et al. Multisystem inflammatory syndrome in children associated with severe acute respiratory syndrome coronavirus 2: a systematic review. [published online ahead of print, 2020 Aug 5] *J Pediatr.* 2020;226:45–54 e1 <https://doi.org/10.1016/j.jpeds.2020.08.003>.
- [6] Cheung EW, Zachariah P, Gorelik M, et al. Multisystem inflammatory syndrome related to COVID-19 in previously healthy children and adolescents in New York City. *JAMA.* 2020 Jul 21;324(3):294–6.
- [7] Feldstein LR, Rose EB, Horwitz SM, et al. Overcoming COVID-19 investigators; CDC COVID-19 response team. Multisystem inflammatory syndrome in U.S. children and adolescents. *N Engl J Med.* 2020 Jul 23;383(4):334–46.
- [8] Verdoni L, Mazza A, Gervasoni A, et al. An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study. *Lancet.* 2020 Jun 6;395(10239):1771–8.
- [9] Webb K, Abraham DR, Faleye A, et al. Cape Town MIS-C-Team. Multisystem inflammatory syndrome in children in South Africa. *Lancet Child Adolesc Health.* 2020 Oct;4(10):e38.
- [10] Whittaker E, Bamford A, Kenny J, et al. PIMS-TS Study Group and EUCLIDS and PERFORM Consortia. Clinical characteristics of 58 children with a pediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2. *JAMA.* 2020 Jul 21;324(3):259–69.
- [11] Davies P, Evans C, Kanthimathinathan HK, et al. Intensive care admissions of children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS) in the UK: a multicentre observational study. *Lancet Child Adolesc Health.* 2020 Sep;4(9):669–77.
- [12] Huang WC, Huang LM, Chang IS, et al. Kawasaki Disease Research Group. Epidemiologic features of Kawasaki disease in Taiwan, 2003–2006. *Pediatrics.* 2009 Mar;123(3):e401–5.
- [13] Yanagawa H, Yashiro M, Nakamura Y, et al. Epidemiologic pictures of Kawasaki disease in Japan: from the nationwide incidence survey in 1991 and 1992. *Pediatrics.* 1995 Apr;95(4):475–9.
- [14] Feldstein LR, Tenforde MW, Friedman KG, et al. Characteristics and outcomes of US children and adolescents with Multisystem Inflammatory Syndrome in Children (MIS-C) compared with severe acute COVID-19. *JAMA.* 2021;325(11):1074–87.
- [15] Son MB, Gauvreau K, Ma L, et al. Treatment of Kawasaki disease: analysis of 27 US pediatric hospitals from 2001 to 2006. *Pediatrics.* 2009 Jul;124(1):1–8.
- [16] Holman RC, Curns AT, Belay ED, et al. Kawasaki syndrome hospitalizations in the United States, 1997 and 2000. *Pediatrics.* 2003 Sep;112(3 Pt 1):495–501.
- [17] Holman RC, Belay ED, Christensen KY, et al. Hospitalizations for Kawasaki syndrome among children in the United States, 1997–2007. *Pediatr Infect Dis J.* 2010 Jun;29(6):483–8.
- [18] Wu MH, Lin MT, Chen HC, et al. Postnatal risk of acquiring kawasaki disease: a Nationwide Birth Cohort Database Study. *J Pediatr.* 2017 Jan;180:80–6 e2.
- [19] Yasuhara J, Watanabe K, Takagi H, Sumitomo N, Kuno T. COVID-19 and multisystem inflammatory syndrome in children: a systematic review and meta-analysis. *Pediatr Pulmonol.* 2021;56(5):837–48.
- [20] Kaushik A, Gupta S, Sood M, et al. A systematic review of multisystem inflammatory syndrome in children associated with SARS-CoV-2 infection. *Pediatr Infect Dis J.* 2020 Nov;39(11):e340–6.
- [21] Capone CA, Subramony A, Sweberg T, et al. Characteristics, cardiac involvement, and outcomes of multisystem inflammatory syndrome of childhood associated with severe acute respiratory syndrome coronavirus 2 infection. *J Pediatr.* 2020 Sep;224:141–5.
- [22] Theocharis P, Wong J, Pushparajah K, et al. Multimodality cardiac evaluation in children and young adults with multisystem inflammation associated with COVID-19 [published online ahead of print, 2020 Aug 7]. *Eur Heart J Cardiovasc Imaging.* 2020;jeaa212. <https://doi.org/10.1093/ehjci/jeaa212>.
- [23] Carter MJ, Fish M, Jennings A, et al. Peripheral immunophenotypes in children with multisystem inflammatory syndrome associated with SARS-CoV-2 infection. *Nat Med.* 2020 Nov;26(11):1701–7.
- [24] Lee PY, Day-Lewis M, Henderson LA, et al. Distinct clinical and immunological features of SARS-CoV-2-induced multisystem inflammatory syndrome in children. *J Clin Invest.* 2020 Nov 2;130(11):5942–50.
- [25] Rowley AH, Shulman ST, Arditi M. Immune pathogenesis of COVID-19-related multisystem inflammatory syndrome in children. *J Clin Invest.* 2020 Nov 2;130(11):5619–21.

- [26] Cheng MH, Zhang S, Porritt RA, et al. Superantigenic character of an insert unique to SARS-CoV-2 spike supported by skewed TCR repertoire in patients with hyperinflammation. *Proc Natl Acad Sci U S A*. 2020;117(41):25254–62.
- [27] Sperotto F, Friedman KG, Son MBF, et al. Cardiac manifestations in SARS-CoV-2-associated multisystem inflammatory syndrome in children: a comprehensive review and proposed clinical approach. *Eur J Pediatr*. 2021 Feb;180(2):307–22.
- [28] Dolhnikoff M, Ferreira Ferranti J, de Almeida Monteiro RA, et al. SARS-CoV-2 in cardiac tissue of a child with COVID-19-related multisystem inflammatory syndrome. *Lancet Child Adolesc Health*. 2020 Oct;4(10):790–4.
- [29] Radia T, Williams N, Agrawal P, et al. Multi-system inflammatory syndrome in children & adolescents (MIS-C): a systematic review of clinical features and presentation [published online ahead of print, 2020 Aug 11]. *Paediatr Respir Rev*. 2020. <https://doi.org/10.1016/j.prrv.2020.08.001> S1526-0542(20)30117-2.
- [30] Ahmed M, Advani S, Moreira A, et al. Multisystem inflammatory syndrome in children: a systematic review. *EclinicalMed*. 2020;26:100527.
- [31] Valverde I, Singh Y, Sanchez-de-Toledo J, et al. Acute cardiovascular manifestations in 286 children with multisystem inflammatory syndrome associated with COVID-19 infection in Europe. *Circulation*. 2021;143(1):21–32.
- [32] Hennon TR, Penque MD, Abdul-Aziz R, et al. COVID-19 associated Multisystem Inflammatory Syndrome in Children (MIS-C) guidelines; a Western New York approach. [published online ahead of print, 2020 May 23] *Prog Pediatr Cardiol*. 2020;101232. <https://doi.org/10.1016/j.ppedcard.2020.101232>.
- [33] Gottlieb M, Long B, Koefman A. The evaluation and management of toxic shock syndrome in the emergency department: a review of the literature. *J Emerg Med*. 2018;54(6):807–14.
- [34] Bridwell R, Long B, Gottlieb M. Neurologic complications of COVID-19. *Am J Emerg Med*. 2020;38(7) 1549.e3–1549.e7.
- [35] Bautista-Rodriguez C, Sanchez-de-Toledo J, Clark BC, et al. Multisystem inflammatory syndrome in children: an international survey. *Pediatrics*. 2021;147(2):e2020024554.
- [36] Young TK, Shaw KS, Shah JK, et al. Mucocutaneous manifestations of multisystem inflammatory syndrome in children during the COVID-19 pandemic. *JAMA Dermatol*. 2021;157(2):207–12.
- [37] Rekhman S, Tannenbaum R, Strunk A, Birabakaran M, Wright S, Garg A. Mucocutaneous disease and related clinical characteristics in hospitalized children and adolescents with COVID-19 and multisystem inflammatory syndrome in children. *J Am Acad Dermatol*. 2021;84(2):408–14.
- [38] BW McCrindle, Rowley AH, Newburger JW, American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee of the Council on Cardiovascular Disease in the Young; Council on Cardiovascular and Stroke Nursing; Council on Cardiovascular Surgery and Anesthesia; and Council on Epidemiology and Prevention, et al. Diagnosis, treatment, and long-term management of kawasaki disease: a scientific statement for health professionals from the American Heart Association. *Circulation*. 2017 Apr 25;135(17):e927–e999.
- [39] Young TK, Shaw KS, Shah JK, et al. Mucocutaneous manifestations of multisystem inflammatory syndrome in children during the COVID-19 pandemic. *JAMA Dermatol*. 2021;157(2):207–12.
- [40] Halepas S, Lee KC, Myers A, Yoon RK, Chung W, Peters SM. Oral manifestations of COVID-2019-related multisystem inflammatory syndrome in children: a review of 47 pediatric patients. *J Am Dent Assoc*. 2021;152(3):202–8.
- [41] Riphagen S, Gomez X, Gonzalez-Martinez C, et al. Hyperinflammatory shock in children during COVID-19 pandemic. *Lancet*. 2020 May 23;395(10237):1607–8.
- [42] Carlin RF, Fischer AM, Pitkowsky Z, et al. Discriminating multisystem inflammatory syndrome in children requiring treatment from common febrile conditions in outpatient settings. *J Pediatr*. 2021;229 26–32.e2.
- [43] Henderson LA, Canna SW, Friedman KG, et al. American College of Rheumatology Clinical Guidance for multisystem inflammatory syndrome in children associated with SARS-CoV-2 and hyperinflammation in pediatric COVID-19: version 1. *Arthritis Rheumatol*. 2020 Nov;72(11):1791–805.
- [44] Belhadjer Z, Méot M, Bajolle F, et al. Acute heart failure in multisystem inflammatory syndrome in children in the context of global SARS-CoV-2 pandemic. *Circulation*. 2020 Aug 4;142(5):429–36.
- [45] Chiotos K, Bassiri H, Behrens EM, et al. Multisystem inflammatory syndrome in children during the coronavirus 2019 pandemic: a case series. *J Pediatric Infect Dis Soc*. 2020;9(3):393–8.
- [46] Blondiaux E, Parisot P, Redheuil A, et al. Cardiac MRI in children with multisystem inflammatory syndrome associated with COVID-19. *Radiology*. 2020;297(3):E283–8.
- [47] Al-Ghafry M, Vagreich A, Malik M, et al. Multisystem Inflammatory Syndrome in Children (MIS-C) and the Prothrombotic State: Coagulation Profiles and Rotational Thromboelastometry in a MIS-C Cohort [published online ahead of print, 2021 Apr 19]. *J Thromb Haemost*. 2021; <https://doi.org/10.1111/jth.15340>. doi:<https://doi.org/10.1111/jth.15340>
- [48] DeLaroché AM, Stankovic C, Ehrman RR, et al. Emergency department screening for multisystem inflammatory syndrome (MIS-C) in children. [published online ahead of print, 2020 Sep 29] *Am J Emerg Med*. 2020. <https://doi.org/10.1016/j.ajem.2020.09.076> S0735-6757(20)30873-1.
- [49] Regan W, O'Byrne L, Stewart K, et al. Electrocardiographic changes in children with multisystem inflammation associated with COVID-19: associated with coronavirus disease 2019. [published online ahead of print, 2021 Jan 13] *J Pediatr*. 2021. <https://doi.org/10.1016/j.jpeds.2020.12.033> S0022-3476(20)31542-0.
- [50] Blumfield E, Levin TL, Kurian J, et al. Imaging findings in multisystem inflammatory syndrome in children (MIS-C) associated with coronavirus disease (COVID-19). *AJR Am J Roentgenol*. 2021 Feb;216(2):507–17.
- [51] Rostad BS, Shah JH, Rostad CA, et al. Chest radiograph features of multisystem inflammatory syndrome in children (MIS-C) compared to pediatric COVID-19. *Pediatr Radiol*. 2021;51(2):231–8.
- [52] Fenlon Iii EP, Chen S, Ruzal-Shapiro CB, Jaramillo D, Maddocks ABR. Extracardiac imaging findings in COVID-19-associated multisystem inflammatory syndrome in children. *Pediatr Radiol*. 2021;51(5):831–9.
- [53] Morparia K, Park MJ, Kalyanaram M, McQueen D, Bergel M, Phatak T. Abdominal imaging findings in critically ill children with multisystem inflammatory syndrome associated with COVID-19. *Pediatr Infect Dis J*. 2021;40(2):e82–3.
- [54] Matsubara D, Kauffman HL, Wang Y, et al. Echocardiographic findings in pediatric multisystem inflammatory syndrome associated with COVID-19 in the United States. *J Am Coll Cardiol*. 2020 Oct 27;76(17):1947–61.
- [55] DeBiasi RL, Song X, Delaney M, et al. Severe coronavirus disease-2019 in children and young adults in the Washington, DC, metropolitan region. *J Pediatr*. 2020;223:199–203 e1.
- [56] Newburger JW, Takahashi M, Gerber MA, et al. Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. *Pediatrics*. 2004;114:1708–33.
- [57] Ronai C, Hamaoka-Okamoto A, Baker AL, et al. Coronary artery aneurysm measurement and Z score variability in Kawasaki disease. *J Am Soc Echocardiogr*. 2015;29:150–7.
- [58] Miller AF, Arichai P, Gravel CA, et al. Use of cardiac point-of-care ultrasound in the Pediatric Emergency Department. [published online ahead of print, 2020 Oct 27] *Pediatr Emerg Care*. 2020. <https://doi.org/10.1097/PEC.0000000000002271>.
- [59] Weiss SL, Peters MJ, Alhazzani W, et al. Surviving Sepsis campaign international guidelines for the management of septic shock and sepsis-associated organ dysfunction in children. *Pediatr Crit Care Med*. 2020 Feb;21(2):e52–106.
- [60] Toubiana J, Poirault C, Corsia A, et al. Kawasaki-like multisystem inflammatory syndrome in children during the covid-19 pandemic in Paris, France: prospective observational study. *BMJ*. 2020 Jun 3;369:m2094.
- [61] Dove ML, Jaggi P, Kelleman M, et al. Multisystem inflammatory syndrome in children: survey of protocols for early hospital evaluation and management. *J Pediatr*. 2021;229:33–40.
- [62] Kaushik S, Aydin SI, Derespina KR, et al. Multisystem inflammatory syndrome in children associated with severe acute respiratory syndrome coronavirus 2 infection (MIS-C): a multi-institutional study from New York City. *J Pediatr*. 2020;224:24–9.
- [63] Schwartz SP, Walker TC, Kihlstrom M, et al. Extracorporeal membrane oxygenation for COVID-19-associated multisystem inflammatory syndrome in a 5-year-old. [published online ahead of print, 2020 Dec 29] *Am Surg*. 2020. <https://doi.org/10.1177/0003134820983198> 3134820983198.
- [64] Heidemann SM, Tilford B, Bauerfeld C, et al. Three cases of pediatric multisystem inflammatory syndrome associated with COVID-19 due to SARS-CoV-2. *Am J Case Rep*. 2020;21:e925779 Published 2020 Aug 13 10.12659/AJCR.925779.
- [65] Kaushik S, Ahluwalia N, Gangadharan S, et al. ECMO support in SARS-CoV2 multisystem inflammatory syndrome in children in a child. [published online ahead of print, 2020 Sep 9] *Perfusion*. 2020. <https://doi.org/10.1177/0267659120954386> 267659120954386.
- [66] World Health Organization. Multisystem inflammatory syndrome in children and adolescents with COVID-19 Published May 15 ; 2020 Available at <https://www.who.int/news-room/commentaries/detail/multisystem-inflammatory-syndrome-in-children-and-adolescents-with-covid-19> (Accessed May 18, 2021).
- [67] Royal College of Paediatric and Child Health. Paediatric multisystem inflammatory syndrome temporally associated with COVID-19 (PIMS) - guidance for clinicians Updated September ; 2020 Available at <https://www.rcpch.ac.uk/resources/paediatric-multisystem-inflammatory-syndrome-temporally-associated-covid-19-pims-guidance> (Accessed May 18, 2021).